Role of LNG-IUS in abnormal uterine bleeding


  • Poonam Mani Department of Obstetrics and Gynecology, Muzaffarnagar Medical College, Muzaffarnagar, Uttar Pradesh, India
  • Nikshima Chhabra Department of Obstetrics and Gynecology, Muzaffarnagar Medical College, Muzaffarnagar, Uttar Pradesh, India
  • Neeta Chaudhary Department of Obstetrics and Gynecology, Muzaffarnagar Medical College, Muzaffarnagar, Uttar Pradesh, India
  • Satuti Setia Chhabra Department of Obstetrics and Gynecology, Kalpana Chawla Institute of Medical Health and Sciences, Karnal, Haryana, India



AUB, Dysmenorrhoea, LNG-IUS, Menometrorrhagia, Menorrhagia, Mirena, Polymenorrhagia


Background: Abnormal uterine bleeding (AUB), is defined as a change in any or a combination of frequency, duration, or amount of bleeding, is a common gynecological complaint that affects 10‑30% of reproductive‑aged women and constitute about one‑third of all outpatient gynecological visits. Mirena is a hormonal intrauterine device classified as a long-acting reversible contraceptive method. Women with heavy menstrual blood loss, the LNG‑IUS can normalize blood flow. This high level of levonorgestrel in the endometrium induces dramatic effects leading to the unique mode of contraceptive and therapeutic action of the LNG‑IUS. Initially developed to decrease the risk of expulsion of the intrauterine contraceptive device by reducing myometrial contractility.

Methods: This study was a prospective interventional study conducted in the department of Obstetrics and Gynaecology, Muzaffarnagar Medical College, Muzaffarnagar, Uttar Pradesh, over a period of 6 months. MIRENA insertion was done in outpatient department. The effectiveness of device was assessed by reduction in amount of bleeding in case of abnormal uterine bleeding and in the form of subjective symptomatic improvement along with improvement in quality of life. Record of menstrual pattern. Pictorial Blood loss Assessment Chart was used to assess the amount of blood loss in each cycle. The women were called for follow-up after 1 month, then 3 months, and then 6 months and asked regarding the relief they have obtained from the antecedent menstrual complaints. Hemoglobin (Hb) estimation was done on the subsequent visits.

Results: The mean subjective percentage reduction of blood loss reduced from 13.64% at the first visit to 72.16% at 6th month and the mean Hb level in our study before treatment was 6.8 which increased to 9.8 at the end of 6 month.

Conclusions: The levonorgestrel-releasing intrauterine system-mirena, provides an incredible nonsurgical alternative in treatment of menorrhagia which is reversible and spares fertility.


Cooper JM. Contemporary management of abnormal uterine bleeding. Preface. Obstet Gynecol Clin North Am. 2000;27(2):11-3.

Wright RC. Hysterectomy: Past, present, and future. Obstet Gynecol. 1969;33(4):560-3.

Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80(1):84-9.

Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, et al. Erratum to “Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system”. Contraception. 2013;88(1):194.

Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5(3):235e41.

Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998;13(5):1218e24.

Engemise SL, Willets JM, Taylor AH, Emembolu JO, Konje JC. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):101e6.

Burton KA, Henderson TA, Hillier SG, Mason JI, Habib F, Brenner RM, et al. Local levonorgestrel regulation of androgen receptor and 17beta-hydrox-ysteroid dehydrogenase type 2 expression in human endometrium. Hum Reprod. 2003;18(12):2610e7.

Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97(8):690-4.

Singh A, Mani P, Prateek S, Yadav L, Gupta E. Impact of levonorgestrel intrauterine system on metabolic parameters. Int J Reprod Contracept Obstet Gynecol. 2019;8(3):830.

Dhakane M, Deshmukh S, Raghuwanshi N, Karode H, Wahane A. Study of medical management of AUB cases in respect with palm coein classification at tertiary care center. Euro J Mole Clin Med. 2021;8(4):193-203.

Singh K, Agarwal C, Pujani M, Raychaudhuri S, Sharma N, Chauhan V, et al. A clinicopathological correlation of International Federation of Gynecology and Obstetrics's palm-COEIN classification of abnormal uterine bleeding: Indian scenario. J Mi Heal. Wolters Kluwer-Medknow. 2019;10(3):147–52 .

Singh K, Bharati G, Prasad D, Kumari S. Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: a conservative approach. Int J Reprod Contracept Obstet Gynecol. 2017;6(2):631-5.

Desai RM. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3(1):20-3.

Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97(3):190–4.

Dhamangaonkar PC, Anuradha K, Saxena A. Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding. J Midlife Heal. 2015;6(1):26-30.






Original Research Articles